At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Research Grants 27 show all


$1.7M
2012

$138.8K
2013

$12M
2014

$44.2M
2015

$967.5K
2016

Publications 1,974 show all

  • 143
    Thalidomide/analogs & derivatives
  • 59
    Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • 53
    Multiple Myeloma/drug therapy
  • 28
    Myelodysplastic Syndromes/drug therapy
  • 24
    Pancreatic Neoplasms/drug therapy
  • 21
    Antineoplastic Agents/therapeutic use
  • 21
    Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • 20
    Antineoplastic Agents/pharmacology
  • 18
    Leukemia, Myeloid, Acute/drug therapy
  • 17
    Psoriasis/drug therapy

Patents 5,779show all

  • 1,499
    A61K - Preparations for medical, dental, or toilet purposes
  • 776
    C07D - Heterocyclic compounds
  • 307
    C07C - Acyclic or carbocyclic compounds
  • 222
    C08G - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
  • 187
    Y02A - Technologies for adaptation to climate change
  • 165
    C12N - Microorganisms or enzymes
  • 152
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 149
    C07K - Peptides
  • 102
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 100
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations

Clinical Trials 1,728show all

587Phase 2437Phase 3244Phase 1166Phase 1/Phase 2135N/A64Other

SEC Filings show all


262
8-K

75
10-Q

24
10-K

Contact Information

Warren, NJ
United States